imatinib mesylate has been researched along with Cancer of the Retina in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barsh, SR; Brennan, RC; Coppess, W; Flores-Otero, J; Garcia-Vargas, A; Goldsmith, ZK; Irvine, AS; Martinez-Ferrer, M; McEwen, MW; Morales-Tirado, VM; Ritter, MK; Wilson, MW; Yuan, K | 1 |
| Antecka, E; Burnier, MN; Fernandes, BF; Rielo de Moura, L; Sanft, DM; Worme, MD; Zoroquiain, P | 1 |
| Ghosh, B; Goel, N; Pangtey, B; Raina, UK; Thakar, M | 1 |
| Antecka, E; Burnier, MN; de Moura, LR; Di Cesare, S; Fernandes, BF; Marshall, JC | 1 |
| Christoforidis, JB; D'Amico, DJ; DeAngelo, DJ | 1 |
| Bartlett, HM; Costakos, D; Mandava, N | 1 |
6 other study(ies) available for imatinib mesylate and Cancer of the Retina
| Article | Year |
|---|---|
Targeting the Platelet-Derived Growth Factor-beta Stimulatory Circuitry to Control Retinoblastoma Seeds.
Topics: Antineoplastic Agents; Blotting, Western; Cell Culture Techniques; Drug Delivery Systems; Enzyme-Linked Immunosorbent Assay; Eye Enucleation; Flow Cytometry; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasm Seeding; NF-kappa B; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Receptor, Platelet-Derived Growth Factor beta; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Signal Transduction; Tumor Cells, Cultured; Vitreous Body | 2018 |
Immunohistochemical Analysis of PDGFR-α, PDGFR-β and c-Abl in Retinoblastoma: Potential Therapeutic Targets.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Child, Preschool; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Infant; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Retinal Neoplasms; Retinoblastoma | 2016 |
Chronic myeloid leukemia presenting with bilateral central retinal vein occlusion and massive retinal infiltrates.
Topics: Adolescent; Allopurinol; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Therapy, Combination; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Male; Piperazines; Proto-Oncogene Proteins c-bcr; Pyrimidines; Retina; Retinal Neoplasms; Retinal Vein Occlusion; Vision Disorders; Visual Acuity | 2012 |
The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Radiation; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasm Invasiveness; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiation Tolerance; Receptor, Platelet-Derived Growth Factor alpha; Retinal Neoplasms; Retinoblastoma | 2013 |
Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retinal Hemorrhage; Retinal Neoplasms; Visual Acuity | 2003 |
Chronic myelogenous leukemia manifested as bilateral proliferative retinopathy.
Topics: Adult; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fluorescein Angiography; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Retinal Neoplasms; Retinal Neovascularization | 2005 |